GlassScriptPhysician profile
April Odom
NPI 1467983486
$13,480.39
in general payments reported to CMS, 2019-2025
27 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $317 · 2023: $7,343 · 2024: $2,591 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,136 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Grant: $700 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Grant | $700.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $5,154.43 | 2023-2024 | Crysvita, Nourianz |
| Abbvie INC. | $1,473.71 | 2023-2024 | |
| Amgen INC. | $759.09 | 2023-2025 | Evenity, Krystexxa |
| Lilly USA, LLC | $686.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Grifols USA, LLC | $598.30 | 2021-2024 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $563.08 | 2024-2025 | Epclusa, Livdelzi |
| Eko Health, INC. | $559.00 | 2021 | |
| Novo Nordisk INC | $546.45 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $451.80 | 2021-2024 | Saphnelo, Airsupra |
| Alexion Pharmaceuticals, INC. | $445.26 | 2021-2024 | |
| Boston Scientific Corporation | $331.95 | 2025 | Apollo Esg System |
| Madrigal Pharmaceuticals | $275.17 | 2025 | Rezdiffra |
| Insulet Corporation | $169.25 | 2025 | Omnipod |
| Alnylam Pharmaceuticals INC. | $168.99 | 2023-2024 | Onpattro |
| Phadia US INC. | $154.11 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $138.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $135.77 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $118.85 | 2025 | Tryvio |
| Otsuka America Pharmaceutical, INC. | $116.88 | 2023 | Rexulti |
| Horizon Therapeutics Plc | $96.37 | 2022 | |
| Coloplast Corp | $93.89 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.46 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $80.71 | 2021 | |
| Neurelis, INC. | $79.94 | 2024 | Valtoco |
| Abbott Laboratories | $63.31 | 2023 | Freestyle Libre 3 |
| Radius Health, INC. | $32.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.